Cargando…
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
Autores principales: | Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280609/ https://www.ncbi.nlm.nih.gov/pubmed/32438482 http://dx.doi.org/10.1111/bjh.16874 |
Ejemplares similares
-
Risk of relapse of multiple myeloma following kidney transplantation
por: Shah, Sapna, et al.
Publicado: (2019) -
Epidemiological characteristics and outcomes of COVID-19 in asymptomatic versus symptomatic patients
por: PIRAEE, ELAHE, et al.
Publicado: (2022) -
Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
por: Ramasamy, Karthik, et al.
Publicado: (2022) -
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy
por: Booth, Stephen, et al.
Publicado: (2021) -
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The RECOVERY-SIRIO randomized trial
por: Navarese, Eliano P., et al.
Publicado: (2022)